Consent given pursuant to sections 14 and 14A for the importation and supply of the therapeutic goods specified - Apotex Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide a comprehensive regulatory framework for therapeutic goods in Australia, aiming to protect public health by ensuring that therapeutic goods are of acceptable quality, safety, and efficacy. The Act was introduced to address the need for a unified legislative approach to the regulation of therapeutic goods, including medicines, medical devices, and other related products. The Therapeutic Goods Act 1989 is administered by the Therapeutic Goods Administration, which operates under the auspices of the Department of Health. The policy objective of the Act is to safeguard public health by regulating therapeutic goods in a manner that ensures their quality, safety, and efficacy while facilitating access to beneficial products. The Act empowers the Administration to take necessary actions to mitigate any risks associated with therapeutic goods, including the ability to grant consents for non-compliant products under certain conditions, as demonstrated by the recent consent granted to Apotex Pty Ltd for the importation and supply of deferiprone products with label discrepancies.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of therapeutic goods, including medicines, medical devices, blood and blood components, tissues, and vaccines. The Act regulates the quality, safety, efficacy, and timely availability of these goods to ensure public health protection and consumer safety. The Therapeutic Goods Administration (TGA) is the Commonwealth authority responsible for administering the Act and ensuring compliance. The Act applies to entities involved in the importation, manufacture, supply, advertising, or sponsorship of therapeutic goods within Australia, including individuals, companies, and other legal entities. The geographic reach of the Act is national, applying to all therapeutic goods marketed or supplied within the Australian jurisdiction. The Act includes provisions for exemptions and exclusions, such as for research purposes or for goods intended for export only, but these are subject to specific conditions and approvals. The application of the Act can be extended or restricted through subordinate instruments, such as therapeutic goods orders and determinations, which provide more detailed requirements and standards for specific types of goods or activities.

Key Provisions

The Therapeutic Goods Act 1989 provides a framework for the regulation of therapeutic goods in Australia. In particular, sections 14 and 14A allow for the issuance of consents that permit deviations from certain regulatory requirements under specific conditions. Under this Act, on 15 January 2015, the delegate of the Secretary of the Department of Health granted Apotex Pty Ltd consent to import and supply deferiprone (FERRIPROX) in tablet and oral solution forms. These products, identified by their Australian Register of Therapeutic Goods (ARTG) numbers, do not meet the labelling requirements specified in clause 3(2)(l) of Therapeutic Goods Order No. 69 (TGO 69). Specifically, the labels do not include the correct sponsor details, which is a non-compliance issue that the consent seeks to address. The obligations imposed on Apotex Pty Ltd under this consent are to ensure that the previously approved labels for the former sponsor, Orphan Australia Pty Ltd, are used. Additionally, Apotex Pty Ltd must have arrangements in place with the former sponsor to promptly refer any queries or complaints concerning the products to the current sponsor. This arrangement ensures that any consumer or patient concerns are handled efficiently and that the quality and safety of the therapeutic goods are maintained. Failure to comply with the conditions outlined in the consent, or any other provisions of the Therapeutic Goods Act 1989, can result in various legal consequences. Under the Act, breaches can lead to civil or criminal penalties. While the specific penalties for breaches of this consent are not detailed in the extract, generally, the Act provides for substantial fines and potential imprisonment for serious offences. The exact penalties depend on the nature and severity of the breach, and are determined in accordance with the provisions of the Act and any relevant regulations or guidelines. The Therapeutic Goods Administration (TGA) has the authority to take enforcement actions, including recalls, prosecution, and imposing financial penalties, to ensure compliance and protect public health.